HBM Holdings Limited Issues Significant Positive Profit Alert for H1 2026: Substantial Revenue and Profit Growth Expected
HBM Holdings Limited (Stock Code: 02142) has issued a positive profit alert that signals strong interim financial results for the six months ended 30 June 2026. The Board of Directors has released an announcement detailing impressive anticipated growth in both revenue and profit, which could have significant implications for shareholders and the company’s share price.
Key Highlights from the Announcement
- Expected Revenue Surge: HBM anticipates revenue for H1 2026 to be in the range of US\$120 million to US\$125 million (approximately HK\$941 million to HK\$980 million), representing a strong increase from US\$101 million in the same period last year.
- Substantial Profit Growth: Net profit is expected to reach between US\$62 million and US\$67 million (HK\$486 million to HK\$525 million).
- Total Adjusted Profit: Adjusted profit (mainly excluding share-based compensation and one-off expenses) is projected to range between US\$70 million and US\$75 million (HK\$549 million to HK\$588 million).
Key Drivers Behind the Strong Performance
- Strategic Global Collaborations: The company highlights ongoing long-term collaborations with leading multinational pharmaceutical companies, including AstraZeneca and Bristol Myers Squibb.
- New Licensing Deals: HBM secured new out-licensing and product collaborations. Notably, the company entered a licensing collaboration with Solstice Oncology and received milestone payments from the advancement of existing partnerships.
- Growth at Nona Biosciences: The strong business growth of subsidiary Nona Biosciences, including revenues from antibody transactions and discovery services (notably with Lonza), also contributed significantly.
Important Information for Shareholders and Potential Investors
- Results Not Yet Audited: The figures are based on preliminary unaudited management accounts and have not yet been reviewed by the audit committee or external auditors. The final results may differ.
- Official Results Release: The company will publish its full interim results for the six months ended 30 June 2026 by the end of August 2026.
- Potential Share Price Impact: The extent of revenue and profit growth, strategic collaborations with global pharma giants, and new licensing deals are all potentially price-sensitive disclosures that could impact HBM’s share price as investors react to the improved outlook.
Board Composition
- Chairman and Executive Director: Dr. Jingsong Wang
- Other Executive Director: Dr. Yiping Rong
- Independent Non-Executive Directors: Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson, Ms. Weiwei Chen
What Investors Should Do
- Investors and shareholders are strongly advised to exercise caution when trading in the company’s securities, as the final audited figures could differ from the preliminary results disclosed.
- It is recommended to review the official interim results announcement once published and to seek advice from professional or financial advisers if in doubt.
Disclaimer: This article is a summary and interpretation of the company’s announcement for informational purposes only. It does not constitute investment advice. Investors should consult the company’s official filings and seek independent professional advice before making any investment decisions.
香港生物醫藥控股有限公司2026年上半年正面盈利預告公佈（粵語版）
香港生物醫藥控股有限公司（HBM Holdings Limited，股份代號：02142） 發佈了一項正面盈利預告，預示截至2026年6月30日止六個月的中期財務業績將非常亮麗。董事會公佈了預期收入和盈利大幅增長的細節，這對股東及公司股價可能產生顯著影響。
公告重點
- 收入大幅增長： 預計2026年上半年收入為1.2億至1.25億美元（約9.41億至9.8億港元），較2025年同期的1.01億美元大幅上升。
- 盈利顯著增長： 淨利潤預計為6,200萬至6,700萬美元（4.86億至5.25億港元）。
- 經調整利潤：（主要扣除股份基礎補償及一次性開支）預計介乎7,000萬至7,500萬美元（5.49億至5.88億港元）。
業績亮點及驅動因素
- 持續拓展全球合作： 公司與世界領先的跨國製藥公司（如阿斯利康 AstraZeneca及百時美施貴寶 Bristol Myers Squibb）保持長期戰略合作。
- 新產品授權協議： 新增創新產品的授權及合作（如與Solstice Oncology的授權協作），以及現有合作推進達成的里程碑付款。
- Nona Biosciences業務高速增長： 子公司Nona Biosciences的抗體交易及發現服務（如與Lonza的合作）帶來可觀收入。
股東及潛在投資者須注意事項
- 業績尚未審核： 公佈數字僅為董事會根據管理賬目初步評估，未經審核委員會或外部審計師審核，最終業績可能有變動。
- 正式業績公佈： 公司將於2026年8月底前正式公佈中期業績。
- 潛在股價敏感信息： 收入及盈利大幅增長、與全球製藥巨頭的合作、新授權協議等均屬可能影響股價的敏感資料。
董事會組成
- 主席及執行董事： 王勁松博士
- 執行董事： 容一平博士
- 獨立非執行董事： Robert Irwin Kamen 博士、葉小平博士、Albert R. Collinson 博士、陳薇薇女士
投資者建議
- 建議股東及投資者於公司證券交易時審慎行事，留意最終審核業績公佈。
- 如有疑問，應參閱正式中期業績公告，或諮詢專業財務顧問。
免責聲明： 本文僅為根據公司公告整理及解讀之資訊，並不構成任何投資建議。投資者應參閱公司正式文件及諮詢專業顧問，作出獨立判斷。
